Product Description
Triclabendazole, a benzimidazole derivative, has been routinely used since 1983 in veterinary medicine to control infections with Fasciola spp. in domestic herbivorous animals. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16307491/)
Mechanisms of Action: Tubulin Inhibitor, Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Dominican Republic | Egypt | France | India | Korea | Malaysia | Pakistan | Slovenia | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Molecular Partners
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Fascioliasis
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01931085 |
NCT01931085 | N/A |
No longer available |
Other |
None |
2021-05-05 |
Treatments|Trial Status |
|
NCT03084926 |
MP0274-CP101 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2021-12-13 |
50% |
2022-01-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04230148 |
6 Years of Age or Older | P4 |
Active, not recruiting |
Fascioliasis |
2026-03-29 |
2026-01-16 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/19/2023 |
News Article |
Triclabendazole Market to Cross US$ 632.1 Mn by 2031 with a Steady 4.1% CAGR, TMR Study |
|
04/01/2022 |
News Article |
Liver Fluke Treatment Market Dynamics and Competitive Scenario Foreacst 2022-2031 |
|
03/08/2022 |
News Article |
Sinusitis Treatment Market to Rise at CAGR of 3.6% during Forecast Period, Observes TMR Study |
|
02/10/2022 |
News Article |
Increase in Prevalence of Fascioliasis to Help Triclabendazole Market Reach US$ 632.1 Mn by 2031, Notes TMR Study |